Navigation Links
New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
Date:9/7/2008

(Toronto, ON, September 8, 2008) In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.

"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. "There is currently no available therapy for type 2 diabetes that patients can receive once a week."

The new treatment, Exenatide once weekly is the first in a new class of long-acting medications that mimic the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating. The report compared outcomes for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week, as in the currently available version of the drug known as Exenatide (Byetta).

In an international multicentre 6-month clinical trial involving 300 eligible patients, 75 per cent of study subjects who received the once-weekly Exenatide got their diabetes under control as defined by reaching target glucose levels. Patients treated with Exenatide once weekly also experienced fewer side effects, had no increased risk of hypoglycemia (decrease in blood sugars) and saw reductions in body weight.

Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple drugs based on GLP-1 action are under active clinical development, and the new once-weekly treatment is expected to undergo Canadian regulatory review as early as 2009.

"Biomedical research reaches patients and improves lives," said Dr. Jim Woodgett, Director of Research at the Samuel Lunenfeld Research Institute. "Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery
'/>"/>

Contact: Nikki Luscombe
luscombe@lunenfeld.ca
416-586-4800 x2046
Samuel Lunenfeld Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landmark study opens door to new cancer, aging treatments
2. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. Why a common treatment for prostate cancer ultimately fails
5. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
6. Childrens national co-leads nationwide study of landmark sickle cell treatment
7. Potatoes may hold key to Alzheimers treatment
8. Blood pressure response to daily stress provides clues for better hypertension treatment
9. Genes newly explained effect on height may change tumor disorder treatment
10. Songbirds may hold key to advances in treatment of brain degeneration
11. Treatment corrects severe insulin imbalance in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... from the King Juan Carlos University (URJC) have carried ... looked at whether spiders were more tolerant of human ... suffer the consequences of changes to their landscape just ... number of spider species is negatively affected by the ...
... researchers from Tel-Aviv University show that predator-prey interactions between ... amphibians are much more complex than expected. The study ... Keys . , "Amphibians are typical insect predators and ... particular. The recently filmed successful attacks of the beetles ...
... from a late-night infomercial: It can twist and bend ... help you fend off disease! But in this ... including the U.S. Department of Energy,s Lawrence Berkeley National ... protein-making machine, the ribosome, at key stages of its ...
Cached Biology News:Spiders suffer from human impact 2Small insects attacks and kill amphibians much bigger than themselves 2Atomic-scale structures of ribosome could help improve antibiotics 2Atomic-scale structures of ribosome could help improve antibiotics 3
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing ... The National Eye Institute (NEI) at the National Institutes ... SBIR grant to develop a drug-eluting intraocular lens (IOL) ... cause of vision loss in people over age 40 ... Dr. Ken Mandell, LayerBio’s Founder and CEO, "There is ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Germany, May 12 , - ... , The number of employees in ... 2006 and 2008. In this same period, the number of,companies ... These,figures were presented today by Dr. Klaus-Dieter Juszak, Chairman of ...
... treatment of Spinal Muscular Atrophy SOUTH PLAINFIELD, N.J. and ... and the Spinal Muscular Atrophy (SMA) Foundation today announced ... SMA Foundation will provide up to $8.5 million in ... of the collaboration to fund a series of research ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 2PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration 3Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3
Request Info...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
Contact us for more information...
Biology Products: